As was largely expected following positive briefing papers earlier this week, the US Food and Drug Administration Oncologic Drugs Advisory Committee (ODAC), in a unanimous vote, recommended approval of Swiss pharma giant Novartis’ (NOVN: VX) generics subsidiary Sandoz’ investigational biosimilar filgrastim - used to help cancer patients fight off infection while undergoing chemotherapy - in the USA.
The Committee also recommended approval of the biosimilar for use in all indications included in the label of the reference product, US biotech major Amgen's (Nasdaq: AMGN) blockbuster Neupogen. Assuming that the FDA agrees with the recommendation, this would become the first biosimilar to be approved by the agency.
Under the brand name Zarzio, the Sandoz biosimilar filgrastim has been marketed in more than 40 countries outside the USA, generating nearly 7.5 million patient-exposure days of experience. It was approved in Europe in 2009. If approved in the USA, Sandoz proposes to market biosimilar filgrastim under the name Zarxio.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze